Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Net Margin of 136.03% for Q1 2026, down 2740.0% year-over-year from 5.15% in Q1 2025, and down 130.07% quarter-over-quarter from 59.13% in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Net Margin for 11 consecutive years, with 136.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 2740.0% year-over-year to 136.03%; the TTM figure through Mar 2026 stood at 90.03% (up 237.0% YoY), while the FY2025 annual figure was 84.55%, up 1635.0% from the prior year.
- Net Margin declined to 136.03% in Q1 2026 per RARE's latest filing, from 59.13% in the prior quarter.
- Across five years, Net Margin topped out at 59.13% in Q4 2025 and bottomed at 270.23% in Q3 2022.
- Historically, Net Margin has averaged 133.13% across 5 years, with a median of 136.03% in 2026.
- Annual changes were most pronounced in 2022 — Net Margin tumbled 54766 bps — and 2023, when it jumped 10741 bps.
- Ultragenyx Pharmaceutical's Net Margin stood at 148.5% in 2022, then surged by 35 bps to 97.17% in 2023, then rose by 19 bps to 78.47% in 2024, then rose by 25 bps to 59.13% in 2025, then sank by 130 bps to 136.03% in 2026.
- Business Quant data shows RARE's Net Margin at 136.03% in Q1 2026, 59.13% in Q4 2025, and 112.81% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -42.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.99% |
| Mar 31, 2026 | -136.03% |
| Dec 31, 2025 | -2.20% |
| Sep 30, 2025 | -112.81% |
| Jun 30, 2025 | -68.86% |
| Mar 31, 2025 | -108.63% |
| Dec 31, 2024 | -81.51% |
| Sep 30, 2024 | -95.71% |
| Jun 30, 2024 | -89.51% |
| Mar 31, 2024 | -156.83% |
| Dec 31, 2023 | -97.17% |
| Sep 30, 2023 | -162.82% |
| Jun 30, 2023 | -147.57% |
| Mar 31, 2023 | -163.16% |
| Dec 31, 2022 | -150.13% |
| Sep 30, 2022 | -270.23% |
| Jun 30, 2022 | -177.03% |
| Mar 31, 2022 | -190.55% |
| Dec 31, 2021 | -149.65% |
| Sep 30, 2021 | -89.41% |